NBRV News and Press, Nabriva Therapeutics plc

2023-07-11 03:46:29 ET Arbutus Biopharma ( NASDAQ: ABUS ) has promoted Karen Sims as Chief Medical Officer and named Christopher Naftzger as General Counsel and Chief Compliance Officer, effective immediately.. Naftzger succeeds Elizabeth Howard&#x...

2023-05-19 08:20:29 ET Lucy Scientific Discovery  ( LSDI ) +43% . Farfetch Limited ( FTCH ) +22% Q1 earnings call release Greenland Technologies Holding ( GTEC ) +14% Q1 earnings call release Nabriva Therapeutics  ( NBRV ) +11% . G...

2023-03-27 10:47:00 ET Gainers: Pyxis Oncology ( PYXS ) +25% . Delcath Systems DCTH +23% . Jounce Therapeutics ( JNCE ) +23% . Alimera Sciences ( ALIM ) +22% . Coeptis Therapeutics ( COEP ) +21% . Losers: Unity Biotechnology ...

Nabriva Therapeutics ( NASDAQ: NBRV ) and Merck ( NYSE: MRK ) have decided to part ways in the U.S. distribution of Sivextro, an antibacterial indicated for skin and skin structure infections (ABSSSI) caused by certain Gram-positive microorganisms. In July 2020, the two compan...

-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...

- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...

Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Ed Arce - H.C. Wainwrig...

Nabriva Therapeutics press release ( NASDAQ: NBRV ): Q3 GAAP EPS of -$4.21 misses by $0.18 . Revenue of $9.15M (+2.8% Y/Y) misses by $1.53M . As of September 30, 2022, Nabriva had $14.8 million in cash, cash equivalents and restricted cash. Based on its current...

- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will rep...